Cervical Cancer-Market Insights, Epidemiology and Market Forecast-2023

Publisher Name :
Date: 31-Mar-2017
No. of pages: 77
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Cervical Cancer- Market Insights, Epidemiology and Market Forecast-2023-Global" Report provides an overview of the disease and global market size of the Cervical Cancer for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Cervical Cancer from 2013-2023. DelveInsight estimates that the therapeutic market size for Cervical Cancer will increase at a Compound Annual Growth Rate of 1.39% and will reach up to USD 231.93 million globally in 2023. The global market size for prophylaxis treatment of Cervical Cancer is expected to grow at a CAGR of 0.71% and reach up to USD 2210.9 Million by 2023.

Cervical Cancer needs to be focused more and more because it adversely affects younger women. It is the fourth most common cause of death among women. Cervical Cancer occurs due to the uncontrolled growth of healthy cells in cervix and forms cervical lesions. It spreads to other tissues such as vagina and uterus. Cervical Cancer is caused by inheritance of defects or mutation in genes. Cervical cancer is also caused due to the infection by the Human Papilloma Virus (HPV) which can infect cells on the surface of the skin and those lining the genitals, anus, mouth and throat, but not the blood or internal organs such as the heart or lungs.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.

Scope

• Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

• Marketed information including available prescription drugs, its patent and exclusivity details.

• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.

• It also provides Market size of Cervical Cancer for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.

• The report will help in developing business strategies by understanding the trends shaping and driving the global market size of the Cervical Cancer for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan.

• Identifying patient populations in the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan Cervical Cancer market to improve product design, pricing, and launch plans.

• To understand the future market competition in the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan Cervical Cancer therapeutics market, as well as prophylaxis and Insightful review of the key market drivers and barriers.

Cervical Cancer-Market Insights, Epidemiology and Market Forecast-2023

Table of Contents

Report Introduction
Cervical Cancer Disease Overview
• Types of Cervical cancer
• Staging of Cervical cancer
• Pathophysiology
• Etiology
• Risk Factors
Diagnosis
Epidemiology and Patient Population of Cervical Cancer
United States
Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Forecasted Incident Cases of Cervical Cancer in United States (2016-2023)
Historical Incident Cases of Cervical Cancer diagnosed by stage in United States (2013-2015)
Forecasted Incident Cases of Cervical Cancer diagnosed by stage in United States (2016-2023)
United Kingdom (UK)
Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2016-2023)
Germany (GE)
Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Germany (2016-2023)
Italy (IT)
Historical Incident Cases of Cervical Cancer in Italy (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Italy (2016-2023)
France (FR)
Historical Incident Cases of Cervical Cancer in France (2013-2015)
Forecasted Incident Cases of Cervical Cancer in France (2016-2023)
Spain (SP)
Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Spain (2016-2023)
Japan (JP)
Historical Incident Cases of Cervical Cancer in Japan (2013-2015)
Forecasted Incident Cases of Cervical Cancer in Japan (2016-2023)
Treatment Landscape
Treatment Algorithm
Treatment by Stages
Cervical Cancer Treatment Regimens
Current Unmet Needs
Cervical Cancer Therapeutic Treatments
Bevacizumab (Avastin)
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Avastin Historical Market Sales 2013-2015
Annual cost of therapy of Avastin
Cervical Cancer Prophylaxis Treatments
Cervarix (Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant)
Advantages & Disadvantages
Product Profile
Efficacy
Safety of Cervarix
Side effects of Drug
Cervarix Historical Market Sales 2012-2015
Cost of therapy of Cervarix
GARDASIL/ GARDASIL 9
Advantages & Disadvantages
Product Profile
Efficacy
Safety
Side effects of Drug
Gardasil Historical Market Sales 2012-2015
Cost of therapy of Gardasil
Pipeline Product (Phase III)
Z-100 (Ancer 20)
Axalimogene filolisbac or AXAL (ADXS11-001)
Gimeracil-Oteracil-Tegafur (S-1, TS-1)
Pipeline Product Analysis
Cervical Cancer Therapeutics Market
Historical Cervical Cancer Therapeutics Market (2013-2015)
Forecasted Cervical Cancer Therapeutics Market (2016-2023)
Global
United States (US)
United Kingdom (UK)
Germany (DE)
Italy (IT)
France (FR)
Spain (SP)
Japan (JP)
Cervical Cancer Prophylaxis Treatment
Historical Cervical Cancer Prophylaxis Treatment (2013-2015)
Forecasted Cervical Cancer Prophylaxis Treatment (2016-2023)
Assumptions and Rationale
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

List of Tables

Table 1: Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Table 2: Forecasted Incident Cases of Cervical Cancer in United States (2017-2023)
Table 3: Historical Incident Cases of Cervical Cancer diagnosed by Cancer Stage, in United States (2013-2015)
Table 4: Forecasted Incident Cases of Cervical Cancer diagnosed by Cancer Stage, in United States (2017-2023)
Table 5: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Table 6: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2017-2023)
Table 7: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Table 8: Forecasted Incident Cases of Cervical Cancer in Germany (2017-2023)
Table 9:Historical Incident Cases of Cervical Cancer inItaly (2013-2015)
Table 10: Forecasted Incident Cases of Cervical Cancer in Italy (2017-2023)
Table 11: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Table 12: Forecasted Incident Cases of Cervical Cancer in France (2017-2023)
Table 13: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Table 14: Forecasted Incident Cases of Cervical Cancer in Spain (2017-2023)
Table 15: Historical Incident Cases of Cervical Cancer in Japan (2013-2015)
Table 16: Forecasted Incident Cases of Cervical Cancer in Japan (2017-2023)
Table 17: Cervical Cancer Therapeutics Market in Global (2013-2023)
Table 18: Historical Cervical Cancer Therapeutics Market in United States (2013-2015)
Table 19: Forecasted Incident Cases of Cervical Cancer in United States (2017-2023)
Table 20: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Table 21: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2017-2023)
Table 22: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Table 23: Forecasted Cervical Cancer Therapeutics Market in Germany (2017-2023)
Table 22: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Table 23: Forecasted Cervical Cancer Therapeutics Market in Italy (2017-2023)
Table 24: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Table 25: Forecasted Cervical Cancer Therapeutics Market in France (2017-2023)
Table 24: Historical Cervical Cancer Therapeutics Market in Japan (2013-2015)
Table 25: Forecasted Cervical Cancer Therapeutics Market in Japan (2017-2023)
Table 26: Historical Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2013-2015)
Table 27: Forecasted Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2017-2023)

List of Figures

Figure 1: Pathophysiology of Cervical Cancer, 2017
Figure 2:Risk Factors of Cervical Cancer, 2017
Figure 3: Historical Incident Cases of Cervical Cancer in United States (2013-2015)
Figure 4: Forecasted Incident Cases of Cervical Cancer in United States (2017-2023)
Figure 5: Historical Incident Cases of Cervical Cancer in United Kingdom (UK) (2013-2015)
Figure 6: Forecasted Incident Cases of Cervical Cancer in United Kingdom (UK) (2017-2023)
Figure 7: Historical Incident Cases of Cervical Cancer in Germany (2013-2015)
Figure 8: Forecasted Incident Cases of Cervical Cancer in Germany (2017-2023)
Figure9:Historical Incident Cases of Cervical Cancer inItaly (2013-2015)
Figure10: Forecasted Incident Cases of Cervical Cancer in Italy (2017-2023)
Figure11: Historical Incident Cases of Cervical Cancer in France (2013-2015)
Figure12: Forecasted Incident Cases of Cervical Cancer in France (2017-2023)
Figure13: Historical Incident Cases of Cervical Cancer in Spain (2013-2015)
Figure14: Forecasted Incident Cases of Cervical Cancer in Spain (2017-2023)
Figure15: Historical Incident Cases of Cervical Cancer in Japan (2013-2015)
Figure16: Forecasted Incident Cases of Cervical Cancer in Japan (2017-2023)
Figure 11:Treatment Algorithm for Cervical Cancer, 2017
Figure 12:Treatment for patients with Stage IA1 of Cervical Cancer, 2017
Figure 13:Treatment for patients with Stage IA2 of Cervical Cancer, 2017
Figure 14:Treatment for patients with Stage IB1 of Cervical Cancer, 2017
Figure 15:Treatment for patients with Stage IB2 to Stage IVA of Cervical Cancer, 2017
Figure 16:Treatment for patients with Stage IVB of Cervical Cancer, 2017
Figure 18: Global Cervical Cancer Therapeutics Market (2013-2023)
Figure13: Historical Cervical Cancer Therapeutics Market in United States (2013-2015)
Figure 14: Forecasted Cervical Cancer Therapeutics Market in United States (2017-2023)
Figure15: Historical Cervical Cancer Therapeutics Market in United Kingdom (2013-2015)
Figure 16: Forecasted Cervical Cancer Therapeutics Market in United Kingdom (2017-2023)
Figure17: Historical Cervical Cancer Therapeutics Market in Germany (2013-2015)
Figure18: Forecasted Cervical Cancer Therapeutics Market in Germany (2017-2023)
Figure19: Historical Cervical Cancer Therapeutics Market in Italy (2013-2015)
Figure 20: Forecasted Cervical Cancer Therapeutics Market in Italy (2017-2023)
Figure 21: Historical Cervical Cancer Therapeutics Market in France (2013-2015)
Figure22: Forecasted Cervical Cancer Therapeutics Market in France (2017-2023)
Figure 23: Historical Cervical Cancer Therapeutics Market in Spain (2013-2015)
Figure24: Forecasted Cervical Cancer Therapeutics Market in Spain (2017-2023)
Figure 25: Historical Cervical Cancer Therapeutics Market in Japan (2013-2015)
Figure26: Forecasted Cervical Cancer Therapeutics Market in Japan (2017-2023)
Figure 27: Historical Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2013-2015)
Figure 28: Forecasted Global Market of Cervical Cancer Prophylaxis Treatment in USD, Million (2017-2023)
  • Oral Mucositis - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 97
    Oral Mucositis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oral Mucositis - Pipeline Review, H2 2017, provides an overview of the Oral Mucositis (Gastrointestinal) pipeline landscape. Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in th......
  • Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
    Published: 16-Aug-2017        Price: US 2000 Onwards        Pages: 427
    Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It usually starts in B lymphocytes. The disease can spread to nearby ......
  • Global Cancer Gene Therapy Market 2017-2021
    Published: 09-Aug-2017        Price: US 3500 Onwards        Pages: 85
    About Cancer Gene Therapy Cancer gene therapy is the treatment of cancer through gene therapy. The therapy uses genetically engineered vectors mostly viruses to deliver a gene into the individual's body. It can be used for both the prevention and treatment of disease. The major therapies used for the treatment are oncolytic virotherapy, gene transfer, and gene-induced immunotherapy. The rising prevalence rate of cancer has been a huge challenge for the global economies as the disease lead......
  • Global Chronic Lymphocytic Leukemia Therapeutics Market Size, Status and Forecast 2022
    Published: 03-Aug-2017        Price: US 3300 Onwards        Pages: 95
    This report studies the global Chronic Lymphocytic Leukemia Therapeutics market, analyzes and researches the Chronic Lymphocytic Leukemia Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - Amgen - Abbott - Roche AG - Novartis - Johnson and Johnson - Sanofi Genzyme Corporation - Akebia Therapeutics - Celgene......
  • Global Lung Cancer Therapeutics Market Size, Status and Forecast 2022
    Published: 03-Aug-2017        Price: US 3300 Onwards        Pages: 91
    This report studies the global Lung Cancer Therapeutics market, analyzes and researches the Lung Cancer Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - Roche - Merck - AstraZeneca - Sanofi-Aventis - Eli Lilly and Company - Abbott - Akebia Therapeutics - Agennix AG Market segment by Regions......
  • Global Breast Cancer Monoclonal Antibodies Market Research Report 2017
    Published: 31-Jul-2017        Price: US 2900 Onwards        Pages: 123
    In this report, the global Breast Cancer Monoclonal Antibodies market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Breast Cancer Monoclonal Antibodies in these regions, from 2012 to 2022 (forecast), covering - North America......
  • Small Cell Lung Cancer - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Small Cell Lung Cancer -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Small Cell Lung Cancer in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Small Cell Lung Cancer. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Small Cell Lung Cancer. The report contains the targ......
  • Soft Tissue Sarcoma - Epidemiology Insights to 2025
    Published: 28-Jul-2017        Price: US 2950 Onwards        Pages: 40
    DelveInsight's "Soft Tissue Sarcoma -Epidemiology Forecast, 2025" provides an overview of the epidemiology trends of Soft Tissue Sarcoma in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Soft Tissue Sarcoma. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical needs associated with the Soft Tissue Sarcoma. The report contains the targeted patient......
  • Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025
    Published: 28-Jul-2017        Price: US 5750 Onwards        Pages: 70
    DelveInsight's "Small Cell Lung Cancer - Market Insights, Epidemiology and Market Forecast - 2025" report provides an overview of the disease and in depth research related to Small Cell Lung Cancer for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025. This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Small Cell Lung Cancer . It enables unde......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs